VTE Prophylaxis in Critical Care: A Comprehensive Clinical Guideline
Evidence-based guideline for venous thromboembolism prevention in critically ill patients, including pharmacologic and mechanical prophylaxis, special populations, and monitoring.
VTE
VTE Prophylaxis in Critical Care — Part 4: Special ICU Populations, HIT & Quality Metrics
VTE prophylaxis in traumatic brain injury, spinal cord injury, neurosurgery, burns, stroke, cardiac surgery, orthopedic trauma, ECMO, thrombocytopenia, active bleeding, pregnancy, and obesity; HIT recognition and alternative anticoagulants; quality metrics and compliance monitoring.
VTE Prophylaxis in Critical Care — Part 3: Mechanical Prophylaxis, IVC Filters & Diagnosis of ICU-Acquired VTE
Evidence for intermittent pneumatic compression and graduated compression stockings, IVC filter indications and complications, screening ultrasound protocols, CTPA decision-making, and transition from prophylaxis to treatment.
VTE Prophylaxis in Critical Care — Part 2: Pharmacologic Prophylaxis
Complete dosing tables for LMWH, UFH, and fondaparinux in ICU patients, renal and obesity dose adjustments, anti-Xa monitoring, key trial evidence (PROTECT, PREVENT, INSPIRATION), and duration of prophylaxis.
VTE Prophylaxis in Critical Care — Part 1: Epidemiology, Risk Factors & Risk Assessment
Incidence and pathophysiology of VTE in critically ill patients, comprehensive ICU risk factors, and complete risk assessment scoring systems including Padua Prediction Score, Caprini Score, and IMPROVE Score.
Cancer-Associated Thrombosis and CVAD-Related VTE: A Comprehensive Clinical Guideline
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Cancer-Associated Thrombosis — Part 5: CVAD-Related Thrombosis Management and Patient Education
Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.
Cancer-Associated Thrombosis — Part 4: Special Situations and Populations
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Cancer-Associated Thrombosis — Part 3: Treatment of Established Cancer-Associated VTE
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Cancer-Associated Thrombosis — Part 2: VTE Prophylaxis in Cancer Patients
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Cancer-Associated Thrombosis — Part 1: Pathophysiology and Risk Assessment
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.